Igor Makhlin, MD
Medical Oncology
Headshot of Igor Makhlin, MD

Igor Makhlin, MD

Medical Oncology
Accepting new patients
Sees patients age 18 and up
Rena Rowan Breast Center
View 1 additional location
Headshot of Igor Makhlin, MD
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

My education and training

  • Geisinger Commonwealth School of MedicineMedical School
  • Johns Hopkins HospitalResidency
  • University of Pennsylvania Health SystemFellowship

Spoken languages

English
English

Reviews

Average Rating

1003 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
October 2026
He is very good at communicating with people , very smart and patient.
Anonymous
October 2026
I trust him very much
Anonymous
October 2026
Compassionate, kind, knowledgeable
Anonymous
October 2026
He is very knowledgeable, takes plenty of time with me and makes good decisions.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Makhlin is a Penn Medicine provider.

Qualifications and experience

All conditions and treatments

Research

Publications

Lawrence-Paul MR, Pan TC, Pant DK, Shih NNC, Chen Y, Belka GK, Makhlin I, Curtis C, DeMichele AM, Chodosh LA. Mutability Dependence of Breast Cancer Metastasis and Latency to Recurrence , Cancer Discov: 2026


Kathleen Doheny Tumor Genomic Testing: Too Little, Too Late , Medscape: 2026


Angus Chen Many cancer patients don’t get genomic tests to guide treatment, study finds , STAT News - https://www.statnews.com/2026/04/07/genomic-tests-needed-for-targeted-cancer-treatments/: 2026


Makhlin I. The Role of Molecular Profiling in Achieving Guideline-Concordant Care-From Sequencing to Survival , JAMA Netw Open, 9: 2026,e265596


Igor Makhlin Dr Makhlin on Data to Support the Use of FES-PET/CT in Breast Cancer Management , Onc Live, 1(1): 2026


Makhlin, Igor Reality Check: Palbociclib in Metastatic Breast Cancer Leveraging Real-World Evidence to Support Effectiveness , JAMA Network Open, Accepted for Publication: 2026


DeMichele A, Clark AS, Shea E, Bayne LJ, Sterner CJ, Rohn K, Dwyer S, Pan TC, Nivar I, Chen Y, Wileyto P, Berry LR, Deluca S, Savage J, Makhlin I, Pant DK, Martin H, Egunsola A, Mears N, Goodspeed BL, Chislock EM, Graves J, Wang J, Shih N, Belka GK, Berry D, Nayak A, Feldman M, Chodosh LA. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial , Nat Med: 2025


Jacob B. Reibel, Christopher A. D’Avella, Igor Makhlin2 , Mengru Wang, Maneet Kaur , Yunzhi Qian, Rebecca L. Maniago, Ivy P. Altomare, Lawrence N. Shulman Guideline concordant osimertinib and durvalumab in two US non-small cell lung cancer cohorts. , ASCO Quality Care Symposium: 2025


Igor Makhlin Dissecting Biologic Risk Using Genomic Assays - Implications for Extended Endocrine Therapy and Beyond , JAMA Network Open - In Press: 2024


Makhlin I, Fallowfield L, Henry NL, Burstein HJ, Somerfield MR, DeMichele A. Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights , JCO Oncol Pract: 2024


View all publications